Log In
Print this Print this

dexlansoprazole (TAK-390MROD)

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionProton pump inhibitor in orally disintegrating tablet formulation
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationGastroesophageal reflux disease (GERD)
Indication DetailsTreat gastroesophageal reflux disease (GERD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today